Cargando…
Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
BACKGROUND: A history of spontaneous preterm birth (sPTB) is a significant risk factor for recurrence. Intra-muscular-7α-hydroxyprogesterone caproate (17P) has been the preventive treatment of choice until the recent “Prolong study” that reported no benefit. OBJECTIVE: To determine the benefit of (1...
Autores principales: | Cohen, Gal, Shavit, Maya, Miller, Netanella, Moran, Rimon, Yagur, Yael, Weitzner, Omer, Ovadia, Michal, Schreiber, Hanoch, Shechter-Maor, Gil, Biron-Shental, Tal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098016/ https://www.ncbi.nlm.nih.gov/pubmed/35551554 http://dx.doi.org/10.1371/journal.pone.0268397 |
Ejemplares similares
-
Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro
por: Sexton, Donal J, et al.
Publicado: (2004) -
The Influence of Prior Obstetrical History on Current 17-Hydroxyprogesterone Caproate Use
por: Ransom, Carla E., et al.
Publicado: (2011) -
Comparison of intravaginal progesterone gel and intramuscular 17-α-hydroxyprogesterone caproate in luteal phase support
por: SATIR, FUNDA, et al.
Publicado: (2013) -
Maternal Characteristics Influencing the Development of Gestational Diabetes in Obese Women Receiving 17-alpha-Hydroxyprogesterone Caproate
por: Egerman, Robert, et al.
Publicado: (2014) -
Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention
por: Garcia, Stephanie M., et al.
Publicado: (2021)